ASPH dysregulates cell death and induces chemoresistance in hepatocellular carcinoma
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2024.217396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Jingtao Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang Province, PR China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Drug Resistance, Neoplasm, Sorafenib. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Health Commission of Heilongjiang Province.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is resistant to multiple conventional drugs including sorafenib, leading to poor prognosis. Inducing cell death has been inextricably pursued in therapeutics, although targeted therapy and immunotherapy have made very limited progress. ASPH (Aspartate β-hydroxylase) can be breakthrough in meeting this unmet clinical need. In HCC, high expression of ASPH enhanced proliferation, migration and invasion. High levels of ASPH predicted worse clinical outcomes of sorafenib-treated HCC patients. Mechanistically, ASPH upregulated SQSTM1/P62 and SLC7A11-GPX4 axis, thereby promoting tumor cell autophagy but blocking ferroptosis. Sorafenib-induced enhancement of autophagy was attenuated by knockout (KO) of ASPH, resulting in sensitization of tumor cells to sorafenib. By silencing ASPH combined with sorafenib, senescence, apoptosis and ferroptosis were mediated, whereas proliferation, migration, invasion, tube formation and stemness were inhibited. As validated by in vivo murine models of HCC, ASPH promoted tumor growth, distant metastasis, and resistance to sorafenib. By contrast, KO ASPH combined with sorafenib effectively inhibited tumor development and progression, including intrahepatic, pulmonary, and splenic metastases. Targeting ASPH generated antitumor efficacy will pave the way for HCC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang Province, PR China.
- Department of Gastroenterology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang Province, PR China.
- Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, Henan Province, PR China.
- Precision Health Program, Department of Radiology, College of Human Medicine, Michigan State University, USA.
- Precision Health Program, Department of Radiology, College of Human Medicine, Michigan State University, USA. Electronic address: dongxi19@msu.edu.
- Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang Province, PR China. Electronic address: zhaibo@hrbmu.edu.cn.
Förderung
- Health Commission of Heilongjiang Province
Zitieren
APA
Li, J., Zhong, G., Hu, F., Zhang, Y., Ren, X., Wang, Z., Ma, S., Zhu, Q., Li, J., Zeng, S., Zhang, Y., Wang, T., Lin, Q., Dong, X., & Zhai, B. (2025). ASPH dysregulates cell death and induces chemoresistance in hepatocellular carcinoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217396
Vancouver
Li J, Zhong G, Hu F, Zhang Y, Ren X, Wang Z, et al. ASPH dysregulates cell death and induces chemoresistance in hepatocellular carcinoma. Cancer Letters. 2025. doi:10.1016/j.canlet.2024.217396
BibTeX
@article{Li2025,
author = {Li, Jingtao and Zhong, Guocai and Hu, Fengli and Zhang, Yingnan and Ren, Xiaohang and Wang, Zongwen and Ma, Shuoheng and Zhu, Qiankun and Li, Junwei and Zeng, Shicong and Zhang, Yao and Wang, Ting and Lin, Qiushi and Dong, Xiaoqun and Zhai, Bo},
title = {ASPH dysregulates cell death and induces chemoresistance in hepatocellular carcinoma},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2024.217396}
}
EUVIMED